Phosphodiesterase 5 Inhibitors
"Phosphodiesterase 5 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
| Descriptor ID |
D058986
|
| MeSH Number(s) |
D27.505.519.389.735.500
|
| Concept/Terms |
Phosphodiesterase 5 Inhibitors- Phosphodiesterase 5 Inhibitors
- Inhibitors, Phosphodiesterase 5
- Phosphodiesterase Type 5 Inhibitors
- PDE-5 Inhibitors
- Inhibitors, PDE-5
- PDE 5 Inhibitors
- PDE5 Inhibitors
- Inhibitors, PDE5
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 5 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 5 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 5 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 5 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 2 | 0 | 2 |
| 2019 | 3 | 0 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase 5 Inhibitors" by people in Profiles.
-
Grandin EW, Gulati G, Nunez JI, Kennedy K, Rame JE, Atluri P, Pagani FD, Kirklin JK, Kormos RL, Teuteberg J, Kiernan MS. Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis. Circ Heart Fail. 2022 04; 15(4):e008613.
-
Bimonte VM, Marampon F, Antonioni A, Fittipaldi S, Ferretti E, Pestell RG, Curreli M, Lenzi A, Vitale G, Brunetti A, Migliaccio S, Aversa A. Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line. Int J Mol Sci. 2021 Jan 13; 22(2).
-
Baker JC, Fintelmann R, Sharifi R, Lee M. Precautions and Monitoring of Patients Taking Phosphodiesterase Type 5 Inhibitors Who are at Risk of Increased Intraocular Pressure. Drugs Aging. 2019 11; 36(11):991-997.
-
Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for Pulmonary Arterial Hypertension. Am J Ther. 2019 Jul/Aug; 26(4):e520-e526.
-
Gulati G, Grandin EW, Kennedy K, Cabezas F, DeNofrio DD, Kociol R, Rame JE, Pagani FD, Kirklin JK, Kormos RL, Teuteberg J, Kiernan M. Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation. Circ Heart Fail. 2019 06; 12(6):e005537.
-
Lindman BR, D?vila-Rom?n VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014 Aug 12; 64(6):541-9.
-
Nguyen H, Amanullah AM. Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease. Rev Cardiovasc Med. 2014; 15(2):158-67.